Pharmacogenetics articles from across Nature Portfolio

The authors conducted a systematic review to examine whether pharmacogenetic testing affects clinical or economic outcomes in patients taking antipsychotic medication.

In the phase 3 STAR trial, subretinal administration of the AAV2-based gene therapy timrepigene emparvovec in patients with choroideremia did not lead to a significant difference in the primary endpoint of 15-letter Early Treatment Diabetic Retinopathy Study (ETDRS) improvement in visual acuity from baseline compared to untreated controls.

We developed a computational method to reveal the drug-induced single-cell transcriptomic landscape. This algorithm enabled us to impute unknown drug-induced single-cell gene expression profiles using tensor imputation, predict cell type-specific drug efficacy, detect cell-type-specific marker genes, and identify the trajectories of regulated biological pathways while considering intercellular heterogeneity.

New research attempts to explore the cause of plasmacytoid dendritic cell hyperactivation in systemic lupus erythematosus by focusing on genetic risk variation.

In personalized medicine, a major aim is to provide the right treatment to the right patient. In this Comment article, Gibson discusses how a more overt and genomics-informed focus on those individuals who are unlikely to benefit from treatment could reduce prescription rates and provide financial and health-care benefits.